Article
Inhibition of Ras for cancer treatment: the search continues.
Future medicinal chemistry - 1 Oct 2011
Baines Antonio T, Xu Dapeng, Der Channing J
Abstract excerpt
The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment. Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic. We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer. Since...
Topics
Join the communities discussing this publication.